Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tumour necrosis factor alpha (TNFalpha) is likely to be involved in the pathogenesis of Wegener's granulomatosis. This paper reviews published clinical trials of the anti-TNFalpha agents etanercept and infliximab with regard to their efficacy and safety in the treatment of Wegener's granulomatosis. On the basis of the high rate of adverse events, particularly an increased incidence of cancers, the use of etanercept in the management of Wegener's granulomatosis is not justified. However, the potential role for infliximab or the as yet untested adalimumab cannot be discounted. The development of novel approaches focusing on blockade of specific molecules including TNFalpha in the treatment of Wegener's granulomatosis is awaited.

Original publication




Journal article


Annals of the rheumatic diseases

Publication Date



64 Suppl 4


iv31 - iv36


Rheumatology Department, Nuffield Orthopaedic Centre, Windmill Road, Oxford OX3 7LD, UK.


Humans, Vasculitis, Tumor Necrosis Factor-alpha, Immunoglobulin G, Receptors, Tumor Necrosis Factor, Antirheumatic Agents, Antibodies, Monoclonal, Treatment Outcome, Wegener Granulomatosis